Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer
18 déc. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer Phase 2 trial demonstrated the safety and efficacy of psilocybin-assisted group therapy for...
Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed
14 déc. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed Sunstone has developed an unrivalled expertise and experience in...
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
06 nov. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two...
Sunstone Therapies Announces Expansion of Innovative Dyad Study
03 oct. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Expansion of Innovative Dyad Study Expansion of Phase 2 pilot trial to assess MDMA-assisted therapy for adjustment disorder in dyads of patients with cancer and a...
Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy
25 août 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy ...
Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)
26 mai 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD) 18-month follow-up of...
Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting
11 mai 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Rockville, Maryland, May...
Sunstone Therapies Announces Publication of Positive Data on Use of Psilocybin Therapy for Patients with Cancer and Major Depression Disorder, in JAMA Oncology
13 avr. 2023 11h16 HE
|
Sunstone Therapies
Phase 2 data shows sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms Use of group setting and 1:1 patient to therapist ratio has...